Multidrug Resistance Modulator

Known as: Multidrug-Resistance Antagonists, Multidrug-Resistance Chemo Sensitizers, Chemosensitizer 
A drug that makes tumor cells more sensitive to the effects of chemotherapy.
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pharmaceutical Preparations

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells.
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. Through the development of a drug… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Abundant evidence suggests that a unifying principle governing the molecular pathology of cancer is the co-dependent aberrant… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2004
Review
2004
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies.
The multidrug resistance-1 (MDR1) gene product, P-glycoprotein (P-gp), and the multidrug resistance-related proteins (MRPs) are… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
The Cancer and Leukemia Group B conducted a phase 3 trial of the P-glycoprotein modulator PSC-833 in untreated acute myeloid… (More)
  • table 1
  • table 3
  • table 2
  • table 4
  • table 5
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
It has been shown that serum levels of interleukin (IL)-6 are elevated in patients with various types of cancer. However, the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
Fumitremorgin C (FTC) is a potent and specific chemosensitizing agent in cell lines selected for resistance to mitoxantrone that… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter.
The P-glycoprotein multidrug transporter functions as an ATP-driven efflux pump for a large number of structurally unrelated… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.
We selected a human colon carcinoma cell line in increasing concentrations of mitoxantrone to obtain a resistant subline, S1-M1-3… (More)
  • table 1
  • figure I
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
1997
Review
1997
Multidrug resistance: molecular mechanisms and clinical relevance
 Multidrug resistance (MDR) describes the phenomenon of simultaneous resistance to unrelated drugs. It has been a decade since… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
1991
Highly Cited
1991
In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
The new nonimmunosuppressive cyclosporin analogue, SDZ PSC 833, is a very potent multidrug-resistance modifier. In vitro, it was… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?